
Conor Stewart
Research expert covering health & pharmaceuticals in the UK & Europe
Get in touch with us nowThe chart is not accessible to screen readers. Please switch to the table view to access the data.
Prostate cancer incidence rates in the United States vary significantly across racial and ethnic groups, with Non-Hispanic Black men facing the highest risk. According to recent data, Non-Hispanic Black males have an incidence rate of 194.8 per 100,000 population, which is substantially higher than the overall rate of 120.2 per 100,000. This stark disparity highlights the importance of targeted screening and prevention efforts to address this health inequality.
The burden of prostate cancer in the U.S. has grown in recent years. In 2025, approximately 313,780 men were projected to be diagnosed with prostate cancer, representing a significant increase from previous years. Despite this rising incidence, mortality rates have shown improvement. In 2022, the prostate cancer death rate was 18.7 per 100,000 men, compared to a rate of almost 39 per 100,000 in the year 1990. This decrease reflects advancements in treatment and early detection.
Age remains a critical risk factor for prostate cancer, with men aged 65 to 84 having a 10.6 percent chance of developing the disease. However, there is encouraging news regarding survival rates. From 2014 to 2020, the five-year relative survival rate for prostate cancer patients in the U.S. was an impressive 97 percent. This high survival rate underscores the importance of early detection and the effectiveness of current treatment options.
* For commercial use only
Basic Account
Starter Account
Professional Account
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Incidence
Survival rates
Deaths
Screening
Overview
* For commercial use only
Basic Account
Starter Account
Professional Account
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.